The Motley Fool
13 Jul 2026, 23:28 UTC · 10w ago
Verdict
Headline takes no side. We score PTCT +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
PTC Therapeutics raised its full-year product revenue guidance to between $750 million and $850 million.
More positive than 92% of claims this week
The company's new PKU drug, Sephience, generated $124.6 million in first-quarter sales, representing a 36% quarterly increase.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 85% of claims this week
PTC Therapeutics maintains a strong liquidity position with approximately $1.89 billion in cash.
More positive than 63% of claims this week
Chief Technical Ops Officer Neil Gregory Almstead sold 2,464 shares of common stock under a preset plan.
Near neutral — 99% of claims this week are stronger
Which stocks this story touches
More positive than 85% of ticker scores this week
The company is described as being in a genuine commercial inflection with strong product revenue growth and raised full-year guidance.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
2h ago
−22.7%
Price is moving against the score
$62.90 vs $81.33 close before publication (Jul 13) · not market-adjusted
PTCT chart →
